Cargando…

The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth

The MET proto-oncogene, encoding the tyrosine kinase receptor for Hepatocyte Growth Factor (HGF) regulates invasive growth, a genetic program that associates control of cell proliferation with invasion of the extracellular matrix and protection from apoptosis. Physiologically, invasive growth takes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luraghi, Paolo, Schelter, Florian, Krüger, Achim, Boccaccio, Carla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Research Foundation 2012
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3438853/ https://www.ncbi.nlm.nih.gov/pubmed/22973229 http://dx.doi.org/10.3389/fphar.2012.00164

Ejemplares similares

On the Pro-Metastatic Stress Response to Cancer Therapies: Evidence for a Positive Co-Operation between TIMP-1, HIF-1α, and miR-210
por: Cui, Haissi, et al.
Publicado: (2012)

MET Oncogene Controls Invasive Growth by Coupling with NMDA Receptor
por: Gallo, Simona, et al.
Publicado: (2022)

MET∆14 promotes a ligand-dependent, AKT-driven invasive growth
por: Cerqua, Marina, et al.
Publicado: (2022)

An Observatory for the MET Oncogene: A Guide for Targeted Therapies
por: Altintas, Dogus M., et al.
Publicado: (2023)

Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer
por: Hyung, Sujin, et al.
Publicado: (2023)

Differential Impact of Cysteine Cathepsins on Genetic Mouse Models of De novo Carcinogenesis: Cathepsin B as Emerging Therapeutic Target
por: Reinheckel, Thomas, et al.
Publicado: (2012)

Pro-Oncogenic c-Met/EGFR, Biomarker Signatures of the Tumor Microenvironment are Clinical and Therapy Response Prognosticators in Colorectal Cancer, and Therapeutic Targets of 3-Phenyl-2H-benzo[e][1,3]-Oxazine-2,4(3H)-Dione Derivatives
por: Lawal, Bashir, et al.
Publicado: (2021)

Combination of Selected MET and EGFR Inhibitors Decreases Melanoma Cells’ Invasive Abilities
por: Simiczyjew, Aleksandra, et al.
Publicado: (2019)

MET inhibition overcomes radiation resistance of glioblastoma stem‐like cells
por: De Bacco, Francesca, et al.
Publicado: (2016)

Integrated investigation and experimental validation of PPARG as an oncogenic driver: implications for prognostic assessment and therapeutic targeting in hepatocellular carcinoma
por: Ran, Yunsheng, et al.
Publicado: (2023)

Editorial: Antimycobacterial drug discovery: Molecular therapeutics and target identification
por: Gunosewoyo, Hendra, et al.
Publicado: (2022)

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase
por: Yao, Hang-Ping, et al.
Publicado: (2021)

The PSI Domain of the MET Oncogene Encodes a Functional Disulfide Isomerase Essential for the Maturation of the Receptor Precursor
por: Altintas, Dogus Murat, et al.
Publicado: (2022)

MicroRNA 483‐3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3/AKT axis
por: Candiello, Ermes, et al.
Publicado: (2023)

MicroRNA-181a Functions as an Oncogene in Gastric Cancer by Targeting Caprin-1
por: Lu, Qiang, et al.
Publicado: (2019)

Targeting MET Amplification as a New Oncogenic Driver
por: Kawakami, Hisato, et al.
Publicado: (2014)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

Editorial: Antimycobacterial drug discovery: molecular therapeutics and target identification, Volume II
por: Gunosewoyo, Hendra, et al.
Publicado: (2023)

A view on EGFR-targeted therapies from the oncogene-addiction perspective
por: Perez, Rolando, et al.
Publicado: (2013)

Molecular Targets for Combined Therapeutic Strategies to Limit Glioblastoma Cell Migration and Invasion
por: Yool, Andrea J., et al.
Publicado: (2020)

Chemoprevention of LA7-Induced Mammary Tumor Growth by SM6Met, a Well-Characterized Cyclopia Extract
por: Oyenihi, Omolola R., et al.
Publicado: (2018)

Exploring the oncogenic roles of LINC00857 in pan-cancer
por: Ren, Xiaomin, et al.
Publicado: (2022)

SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells
por: Jenke, Robert, et al.
Publicado: (2020)

The Met oncogene and basal-like breast cancer: another culprit to watch out for?
por: Gastaldi, Stefania, et al.
Publicado: (2010)

Epidermal Growth Factor Receptor: A Potential Therapeutic Target for Diabetic Kidney Disease
por: Sheng, Lili, et al.
Publicado: (2021)

Activating mutation in MET oncogene in familial colorectal cancer
por: Neklason, Deborah W, et al.
Publicado: (2011)

Editorial: Therapeutic targeting of splicing variants in cancer
por: Sarvari, Pouya, et al.
Publicado: (2023)

Targeting Aberrant Expression of STAT3 and AP-1 Oncogenic Transcription Factors and HPV Oncoproteins in Cervical Cancer by Berberis aquifolium
por: Singh, Tejveer, et al.
Publicado: (2021)

ERBB3 as a therapeutic target in glioblastoma: overexpression can make the difference
por: De Bacco, Francesca, et al.
Publicado: (2021)

Ferroptosis: A new therapeutic target for bladder cancer
por: Zeng, Fan, et al.
Publicado: (2022)

HGF/c-Met: A Key Promoter in Liver Regeneration
por: Zhao, Yang, et al.
Publicado: (2022)

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer
por: Sun, Dantong, et al.
Publicado: (2023)

Editorial: Ferroptosis as new therapeutic targets in cancer: From molecular mechanisms to therapeutic opportunities
por: Chen, Jian, et al.
Publicado: (2022)

Targeting Super-Enhancers as a Therapeutic Strategy for Cancer Treatment
por: He, Yi, et al.
Publicado: (2019)

Therapeutic Implications of FABP4 in Cancer: An Emerging Target to Tackle Cancer
por: Sun, Naihui, et al.
Publicado: (2022)

β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer
por: Blandin, Anne-Florence, et al.
Publicado: (2015)

Metabolism-Based Therapeutic Strategies Targeting Cancer Stem Cells
por: Jagust, Petra, et al.
Publicado: (2019)

Compounds targeting ferroptosis in breast cancer: progress and their therapeutic potential
por: Xu, Chuchu, et al.
Publicado: (2023)

Pan-cancer analyses identify DCBLD2 as an oncogenic, immunological, and prognostic biomarker
por: Xie, Pan, et al.
Publicado: (2022)

Characterization of Kinesin Family Member 2C as a Proto-Oncogene in Cervical Cancer
por: Yang, Jing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_deq0iq3amtcfg2r1i2ijrrq1um